Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMEC add-on to FF/VI versus placebo add-on in COPD (Study 2)
2013-002239-44Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of umeclidinium, fluticasone and vilanterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Trough Forced Expiratory Volume in One Second (FEV1) on Day 85. Started Jul 2013; status: completed.
02
Drugs
umeclidiniumfluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-002239-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002239-44.